MGMT and central nervous system cancer: After screening multiple glioma cell lines with MSP, western blot analysis and bisulfite sequencing (BiSEQ), we selected LN18 human glioma cells, given the unmethylated MGMT status within target regions of interest and high levels of de novo MGMT expression (Fig. S1).